Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The study population will include all patients undergoing elective CABG. Consent and
randomization will occur before surgery. Total 500 patients undergoing elective CABG will be
randomly assigned into three groups with 1:1:1 ratio(167 patients per group) in this
open-label study. All the enrolled patients will stop oral antiplatelet drugs according to
local protocol before the surgery. Within the first 24 hours after surgery, study medication
should be restarted and continued for 12 months. Arm A will restart oral antiplatelet drugs
by giving aspirin 100mg qd, Arm B will also restart oral antiplatelet drugs by giving
ticagrelor 90mg bid plus aspirin 100mg qd and Arm C will also restart oral antiplatelet drugs
by giving ticagrelor 90mg bid. Treatment will continue for 12 months, at which time patients
will undergo a multislice computed tomography angiography to assess vein graft patency.
This study is designed to show the superiority of ticagrelor and ticagrelor plus aspirin as
compared with aspirin monotherapy respectively for the 1-year primary efficacy end point of
vein graft patency.